1. Executive Summary |
2. Global Graft vs Host Disease Treatment Market Introduction |
2.1. Global Graft vs Host Disease Treatment Market – Taxonomy |
2.2. Global Graft vs Host Disease Treatment Market –Definitions |
2.2.1. By Drug Class |
2.2.2. By Disease Type |
2.2.3. By Route of Administration |
2.2.4. By Distribution Channel |
2.2.5. By Region |
3. Global Graft vs Host Disease Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Graft vs Host Disease Treatment Market Dynamic Factors – Impact Analysis |
3.6. Global Graft vs Host Disease Treatment Market – Competition Landscape |
4. Global Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 |
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Graft vs Host Disease Treatment Market, By Drug Class, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.1. Monoclonal Antibodies |
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Immunosuppressive Drugs |
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Steroids |
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. TNF Inhibitors |
5.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Tyrosine Kinase Inhibitors |
5.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global Graft vs Host Disease Treatment Market, By Disease Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.1. Acute Graft vs Host Disease |
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Chronic Graft vs Host Disease |
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Graft vs Host Disease Treatment Market, By Route of Administration, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.1. Oral |
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parenteral |
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Graft vs Host Disease Treatment Market, By Distribution Channel, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Graft vs Host Disease Treatment Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
9.1. North America |
9.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Region, 2022-2028 |
10. North America Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
10.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Monoclonal Antibodies |
10.1.2. Immunosuppressive Drugs |
10.1.3. Steroids |
10.1.4. TNF Inhibitors |
10.1.5. Tyrosine Kinase Inhibitors |
10.1.6. Others |
10.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Acute Graft vs Host Disease |
10.2.2. Chronic Graft vs Host Disease |
10.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Oral |
10.3.2. Parenteral |
10.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Hospital Pharmacies |
10.4.2. Retail Pharmacies |
10.4.3. Online Pharmacies |
10.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. USA |
10.5.2. Canada |
10.6. North America Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
10.7. North America Graft vs Host Disease Treatment Market Dynamics – Trends |
11. Europe Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
11.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Monoclonal Antibodies |
11.1.2. Immunosuppressive Drugs |
11.1.3. Steroids |
11.1.4. TNF Inhibitors |
11.1.5. Tyrosine Kinase Inhibitors |
11.1.6. Others |
11.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Acute Graft vs Host Disease |
11.2.2. Chronic Graft vs Host Disease |
11.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Oral |
11.3.2. Parenteral |
11.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Hospital Pharmacies |
11.4.2. Retail Pharmacies |
11.4.3. Online Pharmacies |
11.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Spain |
11.5.5. Italy |
11.5.6. Russia |
11.5.7. Rest of Europe |
11.6. Europe Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
11.7. Europe Graft vs Host Disease Treatment Market Dynamics – Trends |
12. Asia-Pacific Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
12.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Monoclonal Antibodies |
12.1.2. Immunosuppressive Drugs |
12.1.3. Steroids |
12.1.4. TNF Inhibitors |
12.1.5. Tyrosine Kinase Inhibitors |
12.1.6. Others |
12.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Acute Graft vs Host Disease |
12.2.2. Chronic Graft vs Host Disease |
12.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Oral |
12.3.2. Parenteral |
12.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Hospital Pharmacies |
12.4.2. Retail Pharmacies |
12.4.3. Online Pharmacies |
12.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. China |
12.5.2. India |
12.5.3. Japan |
12.5.4. ASEAN |
12.5.5. Australia & New Zealand |
12.5.6. Rest of Asia-Pacific |
12.6. Asia-Pacific Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
12.7. Asia-Pacific Graft vs Host Disease Treatment Market Dynamics – Trends |
13. Latin America Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
13.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Monoclonal Antibodies |
13.1.2. Immunosuppressive Drugs |
13.1.3. Steroids |
13.1.4. TNF Inhibitors |
13.1.5. Tyrosine Kinase Inhibitors |
13.1.6. Others |
13.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Acute Graft vs Host Disease |
13.2.2. Chronic Graft vs Host Disease |
13.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Oral |
13.3.2. Parenteral |
13.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Hospital Pharmacies |
13.4.2. Retail Pharmacies |
13.4.3. Online Pharmacies |
13.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Mexico |
13.5.3. Rest of Latin America |
13.6. Latin America Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
13.7. Latin America Graft vs Host Disease Treatment Market Dynamics – Trends |
14. Middle East and Africa Graft vs Host Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
14.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Monoclonal Antibodies |
14.1.2. Immunosuppressive Drugs |
14.1.3. Steroids |
14.1.4. TNF Inhibitors |
14.1.5. Tyrosine Kinase Inhibitors |
14.1.6. Others |
14.2. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.2.1. Acute Graft vs Host Disease |
14.2.2. Chronic Graft vs Host Disease |
14.3. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Oral |
14.3.2. Parenteral |
14.4. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Hospital Pharmacies |
14.4.2. Retail Pharmacies |
14.4.3. Online Pharmacies |
14.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Gulf Cooperation Council (GCC) Countries |
14.5.2. South Africa |
14.5.3. Rest of MEA |
14.6. MEA Graft vs Host Disease Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
14.7. MEA Graft vs Host Disease Treatment Market Dynamics – Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. F. Hoffmann-La Roche Ltd. |
15.2.2. AbbVie, Inc. |
15.2.3. Bristol-Myers Squibb |
15.2.4. Pfizer, Inc. |
15.2.5. Baxter International plc |
15.2.6. Novartis AG |
15.2.7. Eli Lilly and Co. |
15.2.8. Shire plc |
15.2.9. Alleran plc |
15.2.10. Caladrius |
15.2.11. Eisai |
15.2.12. Anterogen |
16. Research Methodology |
17. Key Assumptions and Acronyms |